Acupuncture as Adjuvant Therapy for Glaucoma: Protocol for a Randomized Controlled Trial.

acupuncture adjunctive therapy adjuvant therapy conventional treatment disease progression efficacy glaucoma intraocular pressure open-angle glaucoma ophthalmic disorders optic optic neuropathy optical coherence tomography

Journal

JMIR research protocols
ISSN: 1929-0748
Titre abrégé: JMIR Res Protoc
Pays: Canada
ID NLM: 101599504

Informations de publication

Date de publication:
08 Oct 2024
Historique:
received: 29 02 2024
accepted: 18 07 2024
revised: 01 07 2024
medline: 8 10 2024
pubmed: 8 10 2024
entrez: 8 10 2024
Statut: epublish

Résumé

Glaucoma is a chronic progressive optic neuropathy that necessitates lifelong treatment to reduce the decline of the optic nerve. Due to the extended and continuous treatments required for patients, complementary therapies are often considered alongside conventional treatments to enhance the effectiveness of the treatment. Acupuncture has demonstrated the potential to lower intraocular pressure in previous clinical trials, making it a promising glaucoma intervention. The primary objective of this study is to conduct a single-center randomized control trial involving patients with glaucoma. Acupuncture will be evaluated as an adjunctive therapy. The trial aims to explore its effectiveness for glaucoma. In this single-center randomized controlled trial, participants (N=50) with primary open-angle glaucoma will be randomly assigned to the treatment group, receiving ophthalmic acupuncture with "De Qi" sensation, or the control group, receiving minimum acupuncture stimulation on nonophthalmic acupoints. The intervention will consist of weekly acupuncture treatments for a total of 6 sessions. Participants will be assessed at 8 time points, which are baseline, during the intervention (6 times), and at a 3-month follow-up. The primary outcome measure is a change in the intraocular pressure before and after each acupuncture treatment. Secondary outcomes will include measurements of heart rate and blood pressure before and after acupuncture, best-corrected visual acuity, visual field, optical coherence tomography, optical coherence tomography angiography, the Glaucoma Symptom Scale, and the Glaucoma Quality of Life-15 questionnaire. Recruitment of participants for the trial commenced on June 28, 2023. A total of 10 participants have been enrolled to test the feasibility of the experiment. We anticipate that the preliminary data from this trial will be completed by December 2025. This trial uses rigorous methodology and comprehensive outcome measurements to assess the clinical efficacy of acupuncture as an adjunctive therapy for glaucoma, providing valuable insights for future clinical treatment guidelines. ClinicalTrials.gov NCT05753137; https://clinicaltrials.gov/study/NCT05753137. DERR1-10.2196/57888.

Sections du résumé

BACKGROUND BACKGROUND
Glaucoma is a chronic progressive optic neuropathy that necessitates lifelong treatment to reduce the decline of the optic nerve. Due to the extended and continuous treatments required for patients, complementary therapies are often considered alongside conventional treatments to enhance the effectiveness of the treatment. Acupuncture has demonstrated the potential to lower intraocular pressure in previous clinical trials, making it a promising glaucoma intervention.
OBJECTIVE OBJECTIVE
The primary objective of this study is to conduct a single-center randomized control trial involving patients with glaucoma. Acupuncture will be evaluated as an adjunctive therapy. The trial aims to explore its effectiveness for glaucoma.
METHODS METHODS
In this single-center randomized controlled trial, participants (N=50) with primary open-angle glaucoma will be randomly assigned to the treatment group, receiving ophthalmic acupuncture with "De Qi" sensation, or the control group, receiving minimum acupuncture stimulation on nonophthalmic acupoints. The intervention will consist of weekly acupuncture treatments for a total of 6 sessions. Participants will be assessed at 8 time points, which are baseline, during the intervention (6 times), and at a 3-month follow-up. The primary outcome measure is a change in the intraocular pressure before and after each acupuncture treatment. Secondary outcomes will include measurements of heart rate and blood pressure before and after acupuncture, best-corrected visual acuity, visual field, optical coherence tomography, optical coherence tomography angiography, the Glaucoma Symptom Scale, and the Glaucoma Quality of Life-15 questionnaire.
RESULTS RESULTS
Recruitment of participants for the trial commenced on June 28, 2023. A total of 10 participants have been enrolled to test the feasibility of the experiment. We anticipate that the preliminary data from this trial will be completed by December 2025.
CONCLUSIONS CONCLUSIONS
This trial uses rigorous methodology and comprehensive outcome measurements to assess the clinical efficacy of acupuncture as an adjunctive therapy for glaucoma, providing valuable insights for future clinical treatment guidelines.
TRIAL REGISTRATION BACKGROUND
ClinicalTrials.gov NCT05753137; https://clinicaltrials.gov/study/NCT05753137.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID) UNASSIGNED
DERR1-10.2196/57888.

Identifiants

pubmed: 39378079
pii: v13i1e57888
doi: 10.2196/57888
doi:

Banques de données

ClinicalTrials.gov
['NCT05753137']

Types de publication

Journal Article Randomized Controlled Trial Clinical Trial Protocol

Langues

eng

Sous-ensembles de citation

IM

Pagination

e57888

Informations de copyright

©Yi-Fang Liao, Yu-Chen Lee, Hui-Ju Lin, Yi-Ching Shao. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 08.10.2024.

Auteurs

Yi-Fang Liao (YF)

Department of Chinese Medicine, China Medical University Hospital, Taichung, Taiwan.
Graduate Institute of Acupuncture Science, College of Chinese Medicine, China Medical University, Taichung, Taiwan.

Yu-Chen Lee (YC)

Department of Chinese Medicine, China Medical University Hospital, Taichung, Taiwan.
Graduate Institute of Acupuncture Science, College of Chinese Medicine, China Medical University, Taichung, Taiwan.

Hui-Ju Lin (HJ)

Department of Ophthalmology, Eye Center, China Medical University Hospital, Taichung, Taiwan.
School of Chinese Medicine, China Medical University, Taichung, Taiwan.

Yi-Ching Shao (YC)

Department of Ophthalmology, Eye Center, China Medical University Hospital, Taichung, Taiwan.
Graduate Institute of Biomedical Sciences, College of Medicine, China Medical University, Taichung, Taiwan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH